{"id":"W3014852378","doi":"10.2196/17117","title":"Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial","year":2020,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chiba University; National Defense Medical College; Japan Agency for Medical Research and Development","keywords":"Medicine; Rituximab; Internal medicine; Multifocal motor neuropathy; Polyradiculoneuropathy; Chronic inflammatory demyelinating polyneuropathy; Placebo; Cohort; Refractory (planetary science); Randomized controlled trial; Clinical endpoint; Clinical trial; Autoantibody; Antibody; Immunology; Pathology; Guillain-Barre syndrome; Mismatch negativity; Lymphoma","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02537849,0.009335279,0.01381834,0.002354915,0.004839417,0.004417594,0.004178006,0.009879328,0.05011748],"category_scores_gemma":[0.0231112,0.003972483,0.005091012,0.002860539,0.005624235,0.004633851,0.00206411,0.009805598,0.01225117],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004757137,"about_ca_system_score_gemma":0.01443655,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001802368,"about_ca_topic_score_gemma":0.003670438,"domain_scores_codex":[0.9817672,0.0109417,0.001522028,0.002119286,0.001573817,0.002075949],"domain_scores_gemma":[0.9882981,0.002140034,0.00239032,0.002076748,0.002462195,0.00263262],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9607043,0.01324768,0.000405243,0.004147341,0.0008363096,0.0001509128,0.0001631057,0.0008928411,0.002094454,0.001425932,0.006446678,0.009485287],"study_design_scores_gemma":[0.9728097,0.01534295,0.0005796081,0.0004793627,0.0002926278,0.00003972929,0.00003064977,0.0007224185,0.0003680847,0.0007057564,0.008574246,0.00005488475],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.005671893,0.0004089831,0.001473055,0.0003025305,0.0005012855,0.9888234,0.001465179,0.0001679663,0.001185711],"genre_scores_gemma":[0.007771184,0.0002979215,0.002455894,0.0004358223,0.0002104851,0.9875116,0.0004622244,0.0000179069,0.0008369467],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.05011748,"threshold_uncertainty_score":0.1676596,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3531484025439489,"score_gpt":0.5751329632100343,"score_spread":0.2219845606660854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}